Monthly Archives: February 2017

The CES Ultra and the Ear – Part 1

The CES ultra underscores its use of its conductive rubber ear clips. The rationale behind it is some interesting science on the ear; especially the vagus nerve and the special role it plays in the body. Read on.

Ref: Wandering nerve could lead to range of therapies

With outposts in nearly every organ and a direct line into the brain stem, the vagus nerve is the nervous system’s superhighway. About 80 percent of its nerve fibers — or four of its five “lanes” — drive information from the body to the brain. Its fifth lane runs in the opposite direction, shuttling signals from the brain throughout the body.

Doctors have long exploited the nerve’s influence on the brain to combat epilepsy and depression. Electrical stimulation of the vagus through a surgically implanted device has already been approved by the U.S. Food and Drug Administration as a therapy for patients who don’t get relief from existing treatments.

Now, researchers are taking a closer look at the nerve to see if stimulating its fibers can improve treatments for rheumatoid arthritis,
SUPER-HIGHWAY The vagus nerve runs from the brain stem down the neck and into the abdomen, reaching a slew of organs in the process.
Nicole Rager Fuller
heart failure, diabetes and even intractable hiccups. In one recent study, vagus stimulation made damaged hearts beat more regularly and pump blood more efficiently. Researchers are now testing new tools to replace implants with external zappers that stimulate the nerve through the skin.

But there’s a lot left to learn. While studies continue to explore its broad potential, much about the vagus remains a mystery. In some cases, it’s not yet clear exactly how the nerve exerts its influence. And researchers are still figuring out where and how to best apply electricity.

“The vagus has far-reaching effects,” says electrophysiologist Douglas Zipes of Indiana University in Indianapolis. “We’re only beginning to understand them.”

The wanderer

Anchored in the brain stem, the vagus travels through the neck and into the chest, splitting into the left vagus and the right vagus. Each of these roads is composed of tens of thousands of nerve fibers that branch into the heart, lungs, stomach, pancreas and nearly every other organ in the abdomen. This broad meandering earned the nerve its name — vagus means “wandering” in Latin — and enables its diverse influence.

cesultra-ear-nerve

The nerve plays a role in a vast range of the body’s functions. It controls heart rate and blood pressure as well as digestion, inflammation and immunity. It’s even responsible for sweating and the gag reflex. “The vagus is a huge communicator between the brain and the rest of the body,” says cardiologist Brian Olshansky of the University of Iowa in Iowa City. “There really isn’t any other nerve like that.”

The FDA approved the first surgically implanted vagus nerve stimulator for epilepsy in 1997. Data from 15 years of vagus nerve stimulation in 59 patients at one hospital suggest that the implant is a safe, effective approach for combating epilepsy in some people, researchers in Spain reported in Clinical Neurology and Neurosurgery in October. Twenty of the patients experienced at least 50 percent fewer seizures; two of those had a 90 percent drop in seizures. The most common side effects were hoarseness, neck pain and coughing. In other research, those effects often subsided when stimulation was stopped.

Early on, researchers studying the effects of vagus stimulation on epilepsy noticed that patients experienced a benefit unrelated to seizure reduction: Their moods improved. Subsequent studies in adults without epilepsy found similar effects. In 2005, the FDA approved vagus nerve stimulation to treat drug-resistant depression.

Although many details about how stimulation affects the brain remain unclear, studies suggest that vagus stimulation increases levels of the neurotransmitter norepinephrine, which carries messages between nerve cells in parts of the brain implicated in mood disorders. Some antidepressant drugs work by boosting levels of norepinephrine. Silencing norepinephrine-producing brain cells in rats erased the antidepressant effect of vagus nerve stimulation, scientists reported in the Journal of Psychiatric Research in September.

Against the swell

Vagus stimulation for epilepsy and depression attempts to target the nerve fibers that shuttle information from body to brain. But its fifth lane, which carries signals from brain to body, is a major conductor of messages controlling the body’s involuntary functions, including heart rhythms and gut activity. The nerve’s southbound fibers can also be a valuable target for stimulation.

Around 15 years ago, scientists determined that the brain-to-body lane of the vagus plays a crucial role in controlling inflammation. While testing the effects of an anti-inflammatory drug in rats, neurosurgeon Kevin Tracey and his colleagues found that a tiny amount of the drug in the rats’ brains blocked the production of an inflammatory molecule in the liver and spleen. The researchers began cutting nerves one at a time to find the ones responsible for transmitting the anti-inflammatory signal from brain to body.

“When we cut the vagus nerve, which runs from the brain stem down to the spleen, the effect was gone,” says Tracey, president and CEO of the Feinstein Institute for Medical Research in Manhasset, N.Y. Later research indicated that stimulating undamaged vagus fibers also had anti-inflammatory effects in animals.

Vagus stimulation prompts release of acetylcholine, Tracey and colleagues reported in 2000. Acetylcholine, a neurotransmitter like norepinephrine, can prevent inflammation.

In 2011, rheumatologist Paul-Peter Tak, of the University of Amsterdam, and his colleagues implanted vagus nerve stimulators into four men and four women who had rheumatoid arthritis, an autoimmune inflammatory condition that causes swollen, tender joints. After 42 days of vagus stimulation — one to four minutes per day — six of the eight arthritis patients experienced at least a 20 percent improvement in their pain and swelling. Two of the six had complete remission, the researchers reported at an American College of Rheumatology conference in 2012.

“From a scientific perspective, it’s an extremely exciting result,” says Tak, who is also a senior vice president at GlaxoSmithKline pharmaceuticals based in Stevenage, England. Despite advances in treatments over the last two decades, rheumatoid arthritis patients need better options, he says. In 2014, Tak and his colleagues reported that vagus stimulation reduced inflammation and joint damage in rats with arthritis. After a week of once-daily, minute-long stimulation sessions, swelling in the rats’ ankles shrank by more than 50 percent, the scientists reported in PLOS ONE.

If these results hold up in future studies, Tak hopes to see the procedure tested in a range of other chronic inflammatory illnesses, including inflammatory bowel disorders such as Crohn’s disease. Studies in animals have shown promise in this area: In 2011, researchers reported in Autonomic Neuroscience: Basic and Clinical that vagus stimulation prevented weight loss in rats with inflamed colons.

Treating inflammatory conditions with vagus stimulation is fundamentally different from treating epilepsy or depression, Tak says. More research with patients will be necessary to develop the technique. “We are entering a completely unknown area, because it’s such a new approach,” he says. There could be financial hurdles as well, he says. But GlaxoSmithKline, which Tak joined after initiating the arthritis study, has purchased shares of SetPoint Medical, a company in Valencia, Calif., that produces implantable vagus nerve stimulators, Tak says.

As he and others put stimulation to the test for inflammation, some scientists are attempting to see if manipulating the nerve can help heal the heart.

The CES Ultra and the Ear – Part 2

Leave a reply

PART 1 PART 2

Ref: Wandering nerve could lead to range of therapies

Taking heart

The vagus nerve has profound control over heart rate and blood pressure. Patients with heart failure, in which the heart fails to pump enough blood through the body, tend to have less active vagus nerves. Trying to correct the problem with electrical stimulation makes sense, says Michael Lauer, director of the cardiovascular sciences division at the National Heart, Lung and Blood Institute in Bethesda, Md. “It’s a great idea.”

cesulyra-ear-clips

Yet so far, results from studies on the effects of vagus stimulation on heart failure have been inconsistent. In 2011, researchers reported in the European Heart Journal that repeated vagus nerve stimulation improved quality of life and the heart’s blood-pumping efficiency in heart failure patients. A vagus stimulation trial of heart failure patients in India published in the Journal of Cardiac Failure in 2014 echoed these results. After six months of therapy, the patients’ left ventricles pumped an average of 4.5 percent more blood per beat.

Last August, however, researchers reported that a six-month clinical trial of vagus stimulation failed to improve heart function in heart failure patients in Europe. This study had the most participants — 87 — but used the lowest average level of electrical stimulation. “All the results thus far are preliminary. The studies that have been finished to date are relatively small,” Lauer says. “But there certainly are promising findings that [suggest] we may be barking up the right tree.”

Another group of scientists is testing more intense vagus stimulation for patients with heart failure. The trial, called INOVATE-HF, is funded by the Israeli medical device company BioControl Medical and uses a higher level of electrical current than the European study that showed no measurable improvements.

“If you try to lower blood pressure and you take a quarter of a pill instead of one pill, blood pressure won’t change,” says cardiologist Peter Schwartz of the IRCCS Istituto Auxologico Italiano in Milan. It’s equally important to use the right dose of vagus stimulation, he says. The new trial is also much larger than earlier studies, with more than 700 patients enrolled internationally. Results are expected by the end of 2016.

Vagus manipulation isn’t limited to heart failure research. It’s also being tried in atrial fibrillation, in which the heart flutters erratically. “When it flutters, it doesn’t really push blood very efficiently,” says clinical electrophysiologist Benjamin Scherlag of the University of Oklahoma in Oklahoma City. Atrial fibrillation is common in people over age 60, Scherlag says, and can ultimately lead to blood clots and strokes. Treatments include drugs that alter heart rhythm or thin the blood, but they don’t work for all patients and some have nasty side effects, Scherlag says.

In the lab, scientists can use high-intensity vagus stimulation to alter heart rhythm and induce atrial fibrillation in animals. But milder stimulation that alters heart rate only slightly, if at all, can actually quell atrial fibrillation, animal studies and one human study show.

Vagus stimulation for atrial fibrillation is still in its infancy, and clinical applications haven’t been adequately tested, says Indiana’s Zipes. “Nevertheless, the concept bears looking into.”

Skin deep

“Vagal nerve stimulation is very nice, but in order to get to the vagus nerve … you have to cut down surgically,” Scherlag says. “This is not the kind of thing you want to do, except under extreme situations.”

cesulyra-ear-clips

But in the ear, tiny fingers of the vagus’s fibers run close to the surface of the skin, primarily under the small flap of flesh, the tragus, that covers the ear’s opening. Studies have explored using stimulation of those fibers through the skin of the ear to treat heart failure, epilepsy and depression, as well as memory loss, headaches and even diabetes — a reflection of the nerve’s control over a variety of hormones in addition to acetylcholine and norepinephrine.

Stimulating the vagus nerve through the ear of diabetic rats lowered and controlled blood sugar concentrations, researchers from China and Boston reported in PLOS ONE in April. The stimulation prompted the rats’ bodies to release the hormone melatonin, which controls other hormones that regulate blood sugar.

Ear-based vagus stimulation appeared to improve memory slightly in 30 older adults in the Netherlands. After stimulation, study subjects were better able to recall whether they had been shown a particular face before, says study coauthor Heidi Jacobs, a clinical neuroscientist at Maastricht University in the Netherlands. The researchers, who reported the work in the May Neurobiology of Aging, plan to investigate whether these effects last over time and exactly how the stimulation affects the brain, Jacobs says.

The ear isn’t the only nonsurgical target. The company electroCore, based in Basking Ridge, N.J., manufactures a small, handheld device that can stimulate the vagus when placed on the throat. The company initially tested the devices to reduce asthma symptoms — relying on the nerve’s anti-inflammatory action. But during testing, patients reported that their headaches were disappearing, says J.P. Errico, CEO of electroCore. Now, the company is investigating the use of an electroCore device to treat chronic cluster headaches, severe headache attacks that can come and go for over a year. People suffering from an average of 67.3 cluster headaches each month experienced around four fewer attacks per week on average when using the device along with standard treatments like drugs, researchers reported in Cephalalgia in September.

Beyond the mystery switch

Even for depression and epilepsy, Tak says, researchers still need to figure out the best ways of stimulating the vagus — exactly where to place a device, and how much of a shock to deliver.

The nerve’s multitasking, two-way nature makes it a challenge to fully understand and control. It’s hard to know exactly what you’re zapping when you stimulate the vagus nerve, says physiologist Gareth Ackland of University College London. He compares vagus stimulation to flipping on a light switch in one room of a house and discovering that this endows other rooms in the house with magical powers. “I’m not sure which room it’s going to happen in, I’m not sure for how long and I’m not sure if, after a while, it’s going to work or not,” he says.

The intensity of electrical current, duration of stimulation and each patient’s health status could all affect the results of a vagus stimulation trial, Ackland says. And it’s possible that a widespread effect, such as suppressing inflammation caused by the immune system, could even be harmful to some patients.

Ackland says that he and his colleagues agree that the vagus nerve is important. And he’s not ready to discount vagus stimulation as a potential therapy for conditions such as heart failure. But he warns that there’s a good deal of biology left to understand. “There’s an awful lot of basic science and basic clinical research that is needed before launching into a variety of potential interventions,” he says.

For Tracey, it’s about way more than the vagus. “Nobody should overpromise that the vagus nerve is the secret to everything,” he says. But with a better map of the body’s nerves and their functions, the lessons learned by studying the vagus could inform future therapies that use nerve stimulation, he says. If researchers can understand and manipulate a particular circuit in a nerve that controls a specific molecule — for example, a protein involved in pain or even cell division — they could zero in on crucial targets. “The promise,” he says, “is for tremendous precision.”

Go back to PART 1

CES, ECP and TENs

Leave a reply

In the 1930s clinicians began to use very high electric currents in order to produce convulsions in patients. This was known as electroconvulsive shock therapy, or ECT, and is still sometimes used in America to treat difficult cases of depression. One of its drawbacks is that patients have to be guarded against breaking bones or doing other physiological damage during the convulsions. Often they are strapped down or given medications to help prevent damaging convulsions. Also, patients complain of memory difficulties that can bother them for up to 6 weeks following the shock treatments. When we first began publishing studies on CES in America back in the 1970s, peer reviewers often read our papers as ECT papers, since they did not know about CES and therefore couldn’t tell the difference. Many early CES papers were turned down by peer reviewers as a result, since the studies didn’t make sense as electroconvulsive shock research.

Another electrical treatment that began in America in the 1970s is transcutaneous electrical nerve stimulation, or TENS. In this treatment, patients typically place electrodes on or near the pain site on their body and stimulate with varying small pulses of electricity, with a wide range of pulse rates available, often going from less than one pulse per second to several thousand pulses per second.

ces ultra in use

In contrast, CES (Cranial Electrotherapy Stimulation) employs gentle electrical stimulation to the head to help normalize brain functioning. CES is safe, effective and affordable. CES units are easy to use.

History of Cranial Electrotherapy Stimulation (CES)

Leave a reply

CES from the early 1900s to 1953 and beyond

While electricity had been used in medicine for some time, in the early 1900s researchers in Europe began trying to find a way to use electricity to put people to sleep. They tried different pulse rates, various intensities of stimulation, direct and alternating (biphasic) current and so forth. They found that if they used a strong enough current, they could put patients into unconsciousness, but the patient tended to regain consciousness the minute the current was turned off.

In 1953 Russian scientists began using 100 pulses per second, limited to from 1 to 4 milliamperes of current, which tended to relax patients and allow them to proceed to a restful sleep. Current was passed through the head with an electrode over each closed eyelid and one over each mastoid process behind the ears. The device was the Somniatron, and the treatment was called “electrosleep.”

CES in America

Japanese bullet train – The Japanese picked up on the ability of the Somniatron to relax persons, and after finding that the engineers on the bullet train tended to become very tense due to the unusual speeds they were driving, and the many unknown safety hazards that might be involved, they began using electrosleep for 20 minutes prior to their run from Tokyo to Kyoto, then using it for another 20 minutes before returning to Tokyo. To do this, the engineers reclined in a dark room with the Somniatron electrodes attached to their head.

Dallas Texas – Ray Gilmer who was an engineer working for an entrepreneurial company just outside Dallas, Texas, saw an article in the Dallas newspaper about the Japanese use of electrosleep to relax its train engineers and went over to investigate. He bought a Somniatron and brought it back to Texas.

Somniatron – Psychiatrists at The University of Texas Medical School in San Antonio, began using the Somniatron experimentally to see what it would do to tense psychiatric patients. They used it very carefully at first, putting it on patients for 30 minutes, three times a week, measuring their sleep, and other stress related disorders such as depression and anxiety. They found it did not do very much to their patients when used this way, so began using it for 30 minutes a day for 5 days a week. They then began seeing results, so switched to double blind experiments and began publishing. (Saul Rosenthal and his group.)
Neurotone – Ray Gilmer then began a new company, NeuroSystems, Inc., in Garland, Texas which is just outside of Dallas, and engineered a unit similar to the Somniatron and named it the Neurotone 101. He began marketing it both for research and medical use. It was about the size of a double wide briefcase, and because of two large rechargeable batteries, weighed some 20 pounds. It pulsed at either 50 or l00 Hz, with a biphasic pulse limited to 1.5 mAmps on a 20% duty cycle. It was researched widely at various American Universities, and medical facilities beginning in the early 1970s.

CES and FDA: Numerous 510(k) units.

In 1976, the U.S. Congress passed a law giving the U.S. Food and Drug Administration control over medical devices. Their new duty was to make sure that every new medical device sold in America was both safe and effective for use.

ces

Since the Neurotone device was being sold in the U.S. prior to the passage of the law, the Neurotone was grandfathered and did not have to pass the new rigid standards of safety and effectiveness.

Because it was then sold for the treatment of insomnia, depression and anxiety, the FDA changed the name of the treatment from “electrosleep” to “cranial electrotherapy stimulation,” the name still in use in the U.S.A., although it is till known as “electrosleep” (CES) in most of the rest of the world, and “neuroelectric therapy” in Great Britain.

If a new company wanted to manufacture and sell a CES device they could either do approximately $80 million in research in animals and humans to show their unit’s safety and clinical effectiveness, or they could show the FDA that their unit was substantially similar to the grandfathered Neurotone device, or its later miniaturized equivalent, the RelaxPak. The process was known as the 510(k) process, referring to the section of the law which provided for it. Perhaps 10 or more CES units have come into the American market through the 510(k) process.

Unlike in most of the world, the FDA first demanded that only licensed physicians could order the use of a CES device, and later changed it so that any licensed medical practitioner could order its use. As of now, physicians, Nurses, chiropractors, licensed psychologists, licensed acupuncturists, licensed massage therapists and so forth can order a CES unit for patient use. In Canada and many other countries, patients can buy them in pharmacies or wherever else they are sold.

CES throughout the world

Tri-annual conference in Gras, Austria, Bulgaria, etc. For many years, an international conference on electrosleep was held, usually in Europe, every three years in which electrosleep researchers gathered from all over the world to present research papers. I went to one of the last ones in Varna, Bulgaria, in 1981, after which the professor who organized them died and the conferences ceased.

Electricity may spark medical treatment

Leave a reply

The treatment seemed as ridiculous as wearing a foil hat to block CIA transmissions: 20 patients with overactive bladder syndrome had electrodes stuck to the soles of their feet for three hours every evening, producing a gentle vibration and causing the big toe to rhythmically bend and straighten.

But after a week or so, the patients’ symptoms had improved more than typically happens with medication, University of Pittsburgh researchers will report at a scientific meeting next month. The patients needed to dash to the bathroom a bit less often and suffered half as many accidents, all without the constipation, dry mouth, and other side effects of standard drugs.

The finding, though preliminary, adds to evidence that therapies for a wide range of ills might come not from medications but from electricity.

brain-waves-ces

Scientists worldwide are exploring the potential of devices dubbed electroceuticals to treat conditions from heart failure and asthma to diabetes, incontinence, and arthritis. The first of the new class of devices, to treat obesity, reached the market this year, and the US government and drug companies are pouring tens of millions of dollars into further research. Enthusiasm for electroceuticals has reached the point that, at a science meeting this year, a researcher listing their many purported benefits jokingly included world peace.

But the excitement is rooted in a small number of studies with relatively few patients, and researchers don’t understand many of the basics about the body’s electrical highways. The field is filled with what several scientists called “cowboys” and with researchers who are “just throwing electric darts at things without knowing what they’re doing,” as one scientist said.

Ranging in size from an iPod to a pencil eraser, electroceuticals are placed on the skin or surgically implanted, where they emit electrical impulses that fire up or quiet down neurons — nerve fibers. Minuscule electric currents normally pulse through nerves to keep the heart, airways, stomach, and other organs functioning and could, potentially, zap them back from malfunctioning.

Unlike drugs, which flood the body with a chemical, electroceuticals promise to be targeted and, proponents argue, virtually free of side effects.

“Everyone wants to use devices to replace drugs,” said neurosurgeon Kevin Tracey, president of the Feinstein Institute for Medical Research on New York’s Long Island. “Every cell in the body is within shouting distance of sensory neurons, so in principle bioelectronics have great potential.”

Hoping to narrow the gulf between principle and reality, the National Institutes of Health will announce this autumn the first funding from its $248 million Stimulating Peripheral Activity to Relieve Conditions, or SPARC, program, and the Pentagon’s blue-skies research arm, DARPA, will disclose recipients of its $80 million ElectRx initiative. The program is part of the Defense agency’s year-old biotechnology unit, which aims to advance discoveries to help wounded warriors and others.

GlaxoSmithKline, the pharmaceutical company, is investing $50 million in bioelectronic startups and $5 million more for basic research to, among other things, map the body’s neurons and show how they might affect chronic diseases, said Kristoffer Famm, who heads the program.

The potential of electrical impulses to treat disease is based on the fact that the body is one big circuit board.

Neurons wend their way into and out of organs like threads in ornate medieval tapestries. As a result, contrary to traditional medical devices such as heart pacemakers that target malfunctioning organs directly, electroceuticals could work long-distance, stimulating neurons far from disease sites.

The tibial nerve near the ankle, for instance, is connected to nerves in the pelvis. Electrically stimulating the former can alleviate chronic pelvic pain, small studies have shown. It has not escaped scientists’ attention that stimulating one point in the body to treat a problem at another is the basis for acupuncture.

The long-distance champion is the vagus nerve, which runs from the brain into every major organ via 100,000 or so branches. That offers both opportunity and risk. The vagus could serve as a therapeutic target for many diseases. But stimulating such a peripatetic nerve could produce “off-target” effects.

“The vagus innervates so many organs, you may be treating obesity but wind up affecting blood pressure,” said gastroenterologist Richard McCallum of Texas Tech University.

Among its many jobs, the vagus carries commands from the brain telling the stomach to expand to receive food and the gastrointestinal tract to process that food. That makes it an inviting target for obesity treatments. Blocking vagal activity interrupts the brain’s commands, said Katherine Tweden, a vice president at Minnesota-based EnteroMedics.

“People physically cannot eat as much and they stay fuller longer because the food doesn’t move out of the stomach as quickly,” she said.

In July, EnteroMedics reported that 162 obese volunteers who received the company’s vBloc electronic device below the esophagus lost about one-quarter of their excess weight after 12 and 18 months. That was only somewhat better than in volunteers who got a sham device, however, leaving the clinical trial short of its goal. Nevertheless, the US Food and Drug Administration had approved the device in January.

One of the most anticipated electroceutical studies stems from a chance 1998 discovery, by the Feinstein Institute’s Tracey, that electrically stimulating the vagus nerve in rats can slash the spleen’s production of inflammatory molecules.

That made him wonder: Could bioelectronics treat inflammatory diseases such as rheumatoid arthritis? In 2011, a company he cofounded, California-based SetPoint Medical, launched a small trial in Europe to find out. A device the size of a stubby pencil and implanted below the collarbone painlessly zaps the vagus for a minute once or twice a day.

More than half the 18 patients saw a reduction of their arthritis symptoms, gaining the ability to fasten buttons, use forks, and garden without pain, SetPoint chief executive Anthony Arnold said.

Scientists are withholding judgment until SetPoint publishes peer-reviewed results, but some are skeptical. Like many early-stage studies, the trial does not include a control group, noted Brendan Canning of Johns Hopkins University, who is investigating whether electrical stimulation can treat respiratory diseases. It therefore cannot rule out the possibility that improvements in arthritis symptoms reflected not the electrical jolt but patients’ expectations.

The body’s electrical byways are two-way streets, so electroceuticals could also target nerves leading away from a malfunctioning organ — such as the heart.

When the heart cannot pump enough blood to meet the body’s needs, it sends the brain an SOS. The brain in turn triggers a host of responses that are meant to be protective but can backfire: the heart muscle might develop scars, and the lungs accumulate fluid, causing more deaths than the heart’s initial malfunction.

“That suggests that if you intervene in this downstream process, you can prevent many of the serious consequences of heart failure,” said physiologist Irving Zucker of the University of Nebraska. When he and his team did that in rats whose heart failure should have been fatal, they reported last year, the animals remained alive.

A human study based on the idea — using an implant from Minneapolis-based CVRx to stimulate nerves leading from the heart to the brain — is raising hopes that what worked in rats could work in people.

Other electroceuticals for heart disease have flamed out, however. Last year, Massachusetts-based Boston Scientific reported that patients who received its implanted device, which stimulated the vagus nerve in the neck, showed no improvement compared with control patients.

That was a serious setback for the field, leading even proponents to call for more basic research into its scientific underpinnings.

“There is no doubt that current devices are sometimes able to elicit a response,” said SPARC coordinator Danilo Tagle, “but it’s hit or miss.”

This story was produced by Stat, a national publication from Boston Globe Media Partners that will launch online this fall with coverage of health, medicine, and life sciences.